a SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya , Bilaspur , India.
b Department of Pharmaceutics, Chandigarh College of Pharmacy , Mohali , India.
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S818-S831. doi: 10.1080/21691401.2018.1513941. Epub 2018 Oct 11.
Vaccines are a significant historical accomplishment in medical science due to its significance in saving millions of lives around the world with a manifold decline in disease burden and health expenditure. Since last decade, extensive efforts in vaccine design based on rational and experimental set up prompts the acknowledgement of several protective antigens; however, the utilization of those antigens as intense safe vaccines is still far beyond their discovery. The advancement of accomplished vaccines will need the combination of numerous strategies. In this way, the vaccine can be capable of provoking an abundant and effective immunization to compete against antigens with minimal/no adverse effects on recipients. First, stable and striking enough on the pharmaceutical point of view. Second, application of rational and realistic approaches to select an appropriate combination of adjuvant, antigen and delivery vehicle in the suitable formulation. Different vaccine adjuvants-delivery system combinations were discussed here elaborately, which are approved/licensed for human vaccines and are in various phases of clinical trials and pre-clinical trials. Challenges/limitations associated with vaccine designing and parameters to be considered, approaches to be applied, using available adjuvants are also detailed.
疫苗是医学科学的一项重大历史成就，因为它在全球范围内挽救了数百万人的生命，使疾病负担和卫生支出大幅减少。自上十年以来，基于合理和实验设置的疫苗设计的广泛努力促使人们认识到了几种保护性抗原；然而，将这些抗原用作强效安全疫苗的应用仍然远远超出了它们的发现。已完成疫苗的进展将需要多种策略的结合。这样，疫苗才能有能力引发丰富有效的免疫反应，与抗原竞争，对接受者几乎没有不利影响。首先，在制药方面要稳定且足够显著。其次，应用合理和现实的方法，选择适当的佐剂、抗原和载体组合，以合适的配方进行应用。本文详细讨论了不同的疫苗佐剂-传递系统组合，这些组合已被批准/许可用于人类疫苗，并处于临床试验和临床前试验的不同阶段。疫苗设计相关的挑战/限制以及需要考虑的参数、应用方法、使用现有佐剂也进行了详细说明。
